Literature DB >> 3042360

Drug treatment of hypertension.

B N Prichard1.   

Abstract

There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicating a diuretic; or contraindication e.g. asthma, and beta-adrenoceptor blocking drugs. beta-Adrenoceptor blocking drugs have the advantage of a long history and of possibly being cardioprotective following myocardial infarction, but they have not yet been established as primary preventive agents in hypertensive patients. The alpha-receptor blocking drugs have the advantage of favourably affecting lipid profile and blood pressure. Therefore, there may be advantages in the use of combined alpha- and beta-blockade. The diuretics, which have the advantage of being inexpensive, are widely used but long term metabolic effects, particularly hypokalaemia, cause concern. This is correctable by co-administration of a potassium sparing diuretic and often preventable by using low doses of the diuretic. Diet may be important as hypokalaemia appears to be less of a problem where potassium intake is high. Experience with calcium antagonists is widening but the use of converting enzyme inhibitors is more limited, and some physicians are less ready to use them as first choice in mild hypertension at present. Drugs like methyldopa, clonidine, the adrenergic neurone inhibitory drugs are now used more as reserve agents. More severe cases of hypertension may require drugs from 2 of the 3 major groups: beta-blocking drugs, vasodilators and diuretics. In some cases, drugs from each of these 3 groups will be required.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042360     DOI: 10.2165/00003495-198800356-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  167 in total

1.  Antihypertensive and beta-adrenoceptor antagonist action of timolol.

Authors:  G Simon; W Kiowski; S Julius
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

2.  Beta-blockers and asthma.

Authors:  P B Decalmer; S S Chatterjee; J M Cruickshank; M K Benson; G M Sterling
Journal:  Br Heart J       Date:  1978-02

3.  Slow channel inhibitors verapamil and nifedipine in the management of hypertension.

Authors:  B A Gould; R S Hornung; S Mann; V Balasubramanian; E B Raftery
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

4.  The development of captopril and its role in the treatment of hypertension.

Authors:  J R Knill
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1982

5.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

7.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

8.  Rate of onset of hypotensive effect of oral labetalol.

Authors:  M J Serlin; M C Orme; M Maciver; G J Green; C M Macnee; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

9.  The influence of sympathetic nervous activity on regression of cardiac hypertrophy.

Authors:  B E Strauer; F Bayer; H M Brecht; W Motz
Journal:  J Hypertens Suppl       Date:  1985-12

10.  Circadian antihypertensive profile of carvedilol (BM 14190).

Authors:  W Meyer-Sabellek; K L Schulte; A Distler; R Gotzen
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.